Spanish pharma spend rise "acceptable":
This article was originally published in Clinica
Executive Summary
Spain's medical technology industry will cautiously welcome news that spending on pharmaceuticals rose annually by 7.9% in 2001, to E7.2 billion ($6.36 billion), according to provisional figures released by the health ministry. The government considers this to be within "acceptable" spending levels, reports El Pais, referring to its policy of limiting pharma spending to three points above GDP growth (including inflation), after the double-figure increases of recent years. A 7.5% rise in 2000, at E6.73 billion, was preceded by average annual growth of 12.9% over the previous 13 years. High spending by the pharma sector has traditionally been seen by the medical devices sector as impacting negatively on funding available to it.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.